Differences Between the East and the West in Managing Advanced-Stage Non-small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Clinical Medicine

Background:

• Lung cancer presents a significant global health challenge with high mortality.
• Late-stage diagnosis often limits curative treatment options for non-small cell lung cancer (NSCLC).
• The identification of oncogenic driver mutations has revolutionized NSCLC treatment over the last two decades.

Purpose of the Study:

• To review recent therapeutic advancements in advanced-stage NSCLC.
• To compare clinical management strategies for NSCLC between Eastern and Western countries.
• To highlight the impact of molecular targeted therapies and immune checkpoint inhibitors.

Main Methods:

• Review of recent clinical studies and therapeutic developments in NSCLC management.
• Comparative analysis of treatment approaches and outcomes in Eastern versus Western populations.
• Focus on molecular targeted therapies, drug-resistant mutations, and immune checkpoint inhibitors.

Main Results:

• Molecular targeted therapies have significantly improved efficacy and quality of life for NSCLC patients with driver mutations.
• Newer therapies effectively address drug-resistant mutations, benefiting refractory or intolerant patients.
• Eastern populations exhibit a higher incidence of epidermal growth factor receptor mutations, suggesting greater benefit from targeted therapies compared to Western populations.

Conclusions:

• Advances in targeted therapy and immune checkpoint inhibitors offer improved survival for advanced NSCLC.
• Regional differences in mutation prevalence necessitate tailored treatment strategies.
• Continued research is crucial for optimizing NSCLC management globally.